Published in final edited form as:

Chemistry. 2008 ; 14(26): 7748–7751. doi:10.1002/chem.200801097.

Stable and Potent Polyvalent Anthrax Toxin Inhibitors: Raft-Inspired Domain Formation in Liposomes Containing PEGylated Lipids

Prakash Rai, David Vance, Vincent Poon, Jeremy Mogridge, and Ravi S Kane

Keywords

liposomes; PEGylation; phase separation; anthrax toxin; inhibitors

The design of polyvalent molecules [1–5], consisting of multiple copies of a ligand attached to a suitable scaffold, represents a promising approach for designing potent inhibitors of pathogens and microbial toxins [1,6–11]. Liposomes are particularly attractive scaffolds for designing polyvalent inhibitors [9,10,12–15]; however, the poor colloidal stability of conventional liposomes and their short circulation times in vivo [16,17] are major obstacles limiting their therapeutic use. We describe the design of highly stable and active polyvalent anthrax toxin inhibitors based on liposomes incorporating polyethylene glycol (PEG)-functionalized lipids (PEGylated liposomes). Furthermore, drawing from the concept of lipid rafts [15,18,19] – domains that are believed to exist in cellular membranes – we have designed heterogeneous domain-containing PEGylated liposomes that are considerably more active than their homogeneous counterparts (Scheme 1). These raft-mimetic PEGylated polyvalent liposomes are attractive not only for designing inhibitors for toxins and pathogens, but also for the design of efficient targeted drug delivery systems.

While liposomes have been investigated extensively for applications in drug delivery, as described above, conventional liposomes are limited in effectiveness because of their low colloidal stability and their rapid uptake by macrophage cells of the immune system, predominantly in the liver and spleen [20]. The ability to enhance the physical stability and extend the circulation lifetime through modification with PEG, achieved by using lipids with PEG attached to their hydrophilic head groups, has proven to be useful in the context of drug delivery [17,20–22]. We first tested whether the use of PEGylated liposomes (Scheme 1b) would enable the design of stable and active polyvalent anthrax lethal toxin (LeTx) inhibitors.

To that end, we made liposomes (100 nm diameter) composed of a 19:1 mixture of 1,2-Distearoyl-*sn*-Glycero-3-Phosphocholine (DSPC) and a pyridyl dithiopropionate derivative of L- α -Distearoyl Phosphatidylethanolamine-N-[Amino(Polyethylene Glycol)2000] (DSPE-PEG2000-PDP). We functionalized these liposomes with an inhibitory peptide HTSTYWLDGAPC [9,23] (4.7%) that binds to the heptameric cell-binding component of anthrax toxin, [PA₆₃]₇, thereby blocking the binding of the toxic enzyme lethal factor (LF). Inhibition of the binding of LF to [PA₆₃]₇ prevents the cytosolic delivery of LF, thereby inhibiting cell death. Peptide-functionalized PEGylated liposomes protected RAW264.7 cells from LeTx with a half maximal inhibitory concentration (IC₅₀) of about 35 nM on a per-peptide basis; control PEGylated liposomes functionalized with thioglycerol showed no inhibitory activity (Fig. 1a). Furthermore, as seen in Fig. 1a, the activity of the polyvalent PEGylated liposomes (Scheme 1b) was comparable to that of conventional (non-PEGylated) DSPC-based liposomes (Scheme 1a) with the same peptide density (20 nM), indicating that the use of PEGylated lipids does not compromise inhibitory activity. Polyvalent inhibitors using

PEGylated liposomes as a scaffold were over four orders of magnitude more potent than the corresponding monovalent peptide, which does not inhibit cytotoxicity at concentrations as high as 2 mM.

We monitored the physical stability of the peptide-functionalized liposomes as a function of storage time at 4 °C by measuring their hydrodynamic radius (R_H) over a period of 21 days. For comparison, we also monitored the size of conventional liposomes over the same period. While conventional liposomes showed a consistent gradual increase in hydrodynamic radius over a 21 day period, PEGylated liposomes showed no significant change in size (Fig. 1b), confirming the greater colloidal stability of PEGylated liposomes as compared to the conventional liposomes.

Having demonstrated the ability to make stable and active polyvalent anthrax lethal toxin inhibitors based on PEGylated liposomes, we next tested the influence of the heterogeneity of the liposomal membrane on stability and inhibitory activity. We previously showed that lateral phase separation provides a general route to increasing the efficiency of polyvalent recognition by conventional liposomes [15]. We hypothesized that laterally phase separated PEGylated liposomes functionalized with an inhibitory peptide would be significantly more stable than the corresponding non-PEGylated or conventional liposomes while still retaining their potency.

To that end, we made liposomes of three different compositions: i) distearoylphosphatidylcholine (DSPC) and DSPE-PEG2000-PDP (molar ratio of 19:1); ii) dioleoylphosphatidylcholine (DOPC), DSPC, and DSPE-PEG2000-PDP (molar ratio of 75:23.8:1.2); and iii) DOPC, DOPE-PEG2000, DSPC, and DSPE-PEG2000-PDP (molar ratio of 71.2:3.8:23.8:1.2). We reasoned that the liposomes composed of the gel-phase lipids DSPC and DSPE-PEG2000-PDP would be homogeneous (Scheme 1b), those composed of the fluid-phase lipid DOPC and the gel-phase lipids DSPC and DSPE-PEG2000-PDP would phase separate with PEG lipids present primarily in domains enriched with gel phase lipids (Scheme 1c), while liposomes of the third composition would phase separate and contain PEGylated lipids in both phases (Scheme 1d). Furthermore, we hypothesized that inhibitors based on phase-separated liposomes would be more potent than inhibitors based on homogeneous liposomes, and that phase separated liposomes containing PEGylated lipids in both phases (Scheme 1d) would be more stable than those having PEGylated lipids in only one phase (Scheme 1c).

To visualize phase separation, we used confocal microscopy to examine giant unilamellar vesicles (GUVs) incorporating 1% of the fluorescent dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiIC), which partitions preferentially into gel phase domains, or TR-DHPE, which partitions preferentially into fluid phase domains. Consistent with our hypothesis, GUVs composed of DSPC, DSPE-PEG2000-PDP, and DiIC appeared to be uniformly fluorescent (Fig. 2a, i), whereas GUVs composed of DOPC, DSPC, DSPE-PEG2000-PDP, and TR-DHPE (Fig. 2a, ii) and GUVs composed of DOPC, DOPE-PEG2000, DSPC, DSPE-PEG2000-PDP, and TR-DHPE (Fig. 2a, iii) showed the presence of dark phase-separated domains.

Next, to test the stability of the liposomes having the three different lipid compositions described above, we used dynamic light scattering to measure the hydrodynamic radii as a function of storage time (Fig. 2b). Again, consistent with our hypothesis, the dynamic light scattering data indicated that phase separated liposomes containing PEGylated lipids in both phases (Scheme 1d) were comparable in stability to homogeneous PEGylated liposomes (Scheme 1b) and significantly more stable than phase separated liposomes containing PEGylated lipids in only one phase (Scheme 1c).

Next, we tested the effect of domain formation on the potency of polyvalent anthrax lethal toxin inhibitors based on PEGylated liposomes. Homogeneous PEGylated liposomes (Scheme 1b) composed of DSPC and DSPE-PEG2000-PDP (molar ratio 95:5) and heterogeneous PEGylated liposomes (Scheme 1d) composed of DOPC, DOPE-PEG2000, DSPC, and DSPE-PEG2000-PDP (molar ratios of 71.2/3.8/23.8/1.2) were allowed to react with the [PA₆₃]₇-binding peptide HTSTYWWLDGAPC [9, 23] and the remaining unreacted thiol-reactive groups on the liposomes were quenched with thioglycerol. We tested the ability of these polyvalent inhibitors to protect RAW264.7 cells from death caused by anthrax lethal toxin. The IC₅₀ for inhibitors based on heterogeneous PEGylated liposomes was more than 10-fold lower than that for homogeneous PEGylated inhibitors on a per-peptide basis, consistent with our hypothesis (Fig. 3a). We used fluorescence resonant energy transfer (FRET) with fluorescein as the donor and rhodamine as the acceptor to confirm that the peptides cluster in lipid domains in the heterogeneous PEGylated liposomes. The homogeneous and heterogeneous PEGylated liposomes were allowed to react with a mixture of fluorescein-labeled and rhodamine-labeled [PA₆₃]₇-binding peptide (1:1 molar ratio; 0.85 % total peptide density). The significant increase in donor quenching and acceptor emission for heterogeneous PEGylated liposomes relative to homogeneous PEGylated liposomes (Fig. 3b), confirming the clustering of peptides into domains in the heterogeneous liposomes.

Collectively, our results demonstrate the ability to design highly active and stable polyvalent inhibitors based on laterally phase separated PEGylated liposomes. These raft-inspired stable liposomes are well-suited for applications ranging from the design of inhibitors for a variety of toxins and pathogens to the targeting of cells for imaging and drug delivery.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge support from NIH grant U01 AI056546 and NSF grant CBET 0608978.

References

1. Mammen M, Choi SK, Whitesides GM. *Angew Chem* 1998;37(20):2755–2794.
2. Mulder A, Huskens J, Reinhoudt DN. *Org Biomol Chem* 2004;2(23):3409–3424. [PubMed: 15565230]
3. Badjic JD, Nelson A, Cantrill SJ, Turnbull WB, Stoddart JF. *Acc Chem Res* 2005;38(9):723–732. [PubMed: 16171315]
4. Kiessling LL, Strong LE, Gestwicki JE. *Annu Rep Med Chem* 2000;35:321–330.
5. Thoma G, Streiff MB, Katopodis AG, Duthaler RO, Voelcker NH, Ehrhardt C, Masson C. *Chem Eur J* 2005;12(1):99–117.
6. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, Pannu NS, Read RJ, Bundle DR. *Nature* 2000;403(6770):669–672. [PubMed: 10688205]
7. Pickens JC, Mitchell DD, Liu JY, Tan XJ, Zhang ZS, Verlinde C, Hol WGJ, Fan EK. *Chem Biol* 2004;11(9):1205–1215. [PubMed: 15380181]
8. Polizzotti BD, Maheshwari R, Vinkenburg J, Kiick KL. *Macromolecules* 2007;40(20):7103–7110. [PubMed: 19169374]
9. Rai P, Padala C, Poon V, Saraph A, Basha S, Kate S, Tao K, Mogridge J, Kane RS. *Nat Biotechnol* 2006;24(5):582–6. [PubMed: 16633350]
10. Basha S, Rai P, Poon V, Saraph A, Gujraty K, Go MY, Sadacharan S, Frost M, Mogridge J, Kane RS. *Proc Natl Acad Sci USA* 2006;103(36):13509–13. [PubMed: 16938891]
11. Joshi A, Saraph A, Poon V, Mogridge J, Kane RS. *Bioconjug Chem* 2006;17(5):1265–9. [PubMed: 16984137]

12. Kingerywood JE, Williams KW, Sigal GB, Whitesides GM. *J Am Chem Soc* 1992;114(18):7303–7305.
13. Spevak W, Nagy JO, Charych DH, Schaefer ME, Gilbert JH, Bednarski MD. *J Am Chem Soc* 1993;115(3):1146–1147.
14. Konkar S, Gupta S, Sampson NS. *Bioorg Med Chem Lett* 2004;14(6):1381–1384. [PubMed: 15006366]
15. Rai PR, Saraph A, Ashton R, Poon V, Mogridge J, Kane RS. *Angew Chem* 2007;46(13):2207–9. [PubMed: 17310484]
16. Gregoriadis G, Senior J. *FEBS Lett* 1980;119(1):43–6. [PubMed: 7428926]
17. Klibanov AL, Maruyama K, Torchilin VP, Huang L. *FEBS Lett* 1990;268(1):235–7. [PubMed: 2384160]
18. Binder WH, Barragan V, Menger FM. *Angew Chem* 2003;42(47):5802–27. [PubMed: 14673910]
19. Simons K, Ikonen E. *Nature* 1997;387(6633):569–72. [PubMed: 9177342]
20. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. *Biochim Biophys Acta* 1991;1070(1):187–92. [PubMed: 1751525]
21. Allen TM, Hansen C. *Biochim Biophys Acta* 1991;1068(2):133–41. [PubMed: 1911826]
22. Lasic DD, Needham D. *Chem Rev* 1995;95(8):2601–2628.
23. Mourez M, Kane RS, Mogridge J, Metallo S, Deschatelets P, Sellman BR, Whitesides GM, Collier RJ. *Nat Biotechnol* 2001;19(10):958–61. [PubMed: 11581662]

Figure 1.

In vitro characterization of peptide-functionalized PEGylated liposomes. a) Percentage inhibition of cytotoxicity vs. concentration for peptide-functionalized PEGylated liposomes (closed circles), thioglycerol-functionalized PEGylated liposomes (open circles), and DSPE-based non-PEGylated peptide-functionalized liposomes (closed triangles). b) Hydrodynamic radii determined by dynamic light scattering for PEGylated liposomes (black bars) and DSPE-based non-PEGylated liposomes (grey bars).

Figure 2.

Characterization of homogeneous and heterogeneous PEGylated liposomes by confocal microscopy and dynamic light scattering. a) Confocal micrographs of GUVs composed of (i) DSPC/DSPE-PEG2000-PDP/DiIC, (ii) DOPC/DSPC/DSPE-PEG2000-PDP/TR-DHPE, and (iii) DOPC/DOPE-PEG2000/DSPC/DSPE-PEG2000-PDP/TR-DHPE. b) Hydrodynamic radius determined by dynamic light scattering for liposomes composed of DSPC/DSPE-PEG2000-PDP (black bars), DOPC/DSPC/DSPE-PEG2000-PDP (grey bars), and DOPC/DOPE-PEG2000/DSPC/DSPE-PEG2000-PDP (white bars).

*, Difference in the R_H value is statistically significant compared to the other samples at 21 days. ($P < 0.02$; unpaired t-test).

Figure 3.

Characterization of phase separated peptide-functionalized PEGylated liposomes. a) Half maximal inhibitory concentration (IC₅₀) values for peptide-functionalized PEGylated liposomes (0.85% density) for homogenous PEGylated liposomes (black bars) and phase separated PEGylated liposomes (grey bars). b) FRET data for phase separated PEGylated liposomes functionalized with fluorescein-labeled peptide alone (closed circles), rhodamine-labeled peptide alone (open circles), a 1:1 mixture of fluorescein-labeled and rhodamine-labeled peptides (open triangles), and for homogenous PEGylated liposomes functionalized with a 1:1 mixture of fluorescein-labeled and rhodamine-labeled peptides (closed triangles).

Scheme 1.

a) Conventional liposome functionalized with peptide. b) PEGylated liposome with a fraction of the PEG lipids functionalized with peptide. c) Phase separated liposome with PEG lipids present only in the gel phase. A fraction of the PEG lipids are attached to peptide. d) Phase separated liposome with PEG lipids present in both phases with peptide attached to only a fraction of PEG lipids in the gel phase. Figure not drawn to scale.